| abstract |
The invention relates to N-[(4-hydroxypiperidine-4-yl) methyl] pyridine-2(1H)-one derivatives which are represented by a general formula I and have double activities of a 5-hydroxytryptamine 1A (5-HT1A) receptor ligand and a selective serotonin reuptake inhibitor (SSRI), stereoisomers thereof, pharmaceutical salts thereof and solvates thereof, and relates to preparation methods for the derivatives, the stereoisomers, the pharmaceutical salts and the solvates, and uses of the derivatives, the stereoisomers, the pharmaceutical salts and the solvates in preventions or treatments of 5-HT system dysfunction associated central nervous system diseases such as depression, anxiety, cognitive deficit, mania, schizophrenia, pain and the like, or uses of the derivatives, the stereoisomers, the pharmaceutical salts and the solvates as tool drugs in studying the 5-HT function and the diseases related to the 5-HT dysfunction, and pharmaceutical compositions comprising the derivatives, the stereoisomers, the pharmaceutical salts and the solvates. Each substituent group in the general formula I is described in the description. |